

Reimbursement Policy:

COVID-19 Vaccine and Monoclonal Antibody Infusions Policy

POLICY NUMBER	EFFECTIVE DATE:	APPROVED BY
RPC20220019	11/09/2020	RPC (Reimbursement Policy Committee)

Reimbursement Guideline Disclaimer: We have policies in place that reflect billing or claims payment processes unique to our health plans. Current billing and claims payment policies apply to all our products, unless otherwise noted. We will inform you of new policies or changes in policies through postings to the applicable Reimbursement Policies webpages on emblemhealth.com and connecticare.com. Further, we may announce additions and changes in our provider manual and/or provider newsletters which are available online and emailed to those with a current and accurate email address on file. The information presented in this policy is accurate and current as of the date of this publication.

The information provided in our policies is intended to serve only as a general reference resource for services described and is not intended to address every aspect of a reimbursement situation. Other factors affecting reimbursement may supplement, modify or, in some cases, supersede this policy. These factors may include, but are not limited to, legislative mandates, physician or other provider contracts, the member’s benefit coverage documents and/or other reimbursement, and medical or drug policies. Finally, this policy may not be implemented the same way on the different electronic claims processing systems in use due to programming or other constraints; however, we strive to minimize these variations.

We follow coding edits that are based on industry sources, including, but not limited to, CPT® guidelines from the American Medical Association, specialty organizations, and CMS including NCCI and MUE. In coding scenarios where there appears to be conflicts between sources, we will apply the edits we determine are appropriate. We use industry-standard claims editing software products when making decisions about appropriate claim editing practices. Upon request, we will provide an explanation of how we handle specific coding issues. If appropriate coding/billing guidelines or current reimbursement policies are not followed, we may deny the claim and/or recoup claim payment.

Overview:

The cost of COVID-19 FDA-authorized vaccine serums and monoclonal antibodies will initially be reimbursed by the government.

EmblemHealth/ConnectiCare will reimburse administration of FDA-authorized COVID-19 vaccines in accordance with applicable state federal laws, regulations and guidance, including the FFCRA, CARES Act and Emergency Use Authorization (EUA) guidance, as outlined below.

Medicare Advantage health plans: Charges for the COVID-19 vaccine administration should be billed to the CMS Medicare Administrative Contractor (Part B). The MAC will reimburse claims for Medicare members with no cost share for the remainder of 2020 and through 2021. Any claims for COVID-19 vaccines or administration charges for COVID-19 vaccines received for Medicare Advantage members will be denied and will inform the provider to resubmit to the member’s MAC. For more information, see the [CMS COVID-19 Provider Toolkit](#).

Commercial/Exchange health plans: EmblemHealth/ConnectiCare will cover the administration of COVID-19 vaccines with no cost share for in- and out-of-network providers during the national public health emergency period. Administration fees will be based on contracted rates or CMS published rates. *NY state-specific rules may also apply.*

Medicaid: EmblemHealth will cover the administration of COVID-19 vaccines with no cost share for in- and out-of-network providers during the national public health emergency period. Administration fees will be based on CMS published rates. *NY state-specific rules and other state Medicaid regulations may apply.*

Reimbursement Policy:

COVID-19 Vaccine and Monoclonal Antibody Infusions Policy

Applicable Coding:

CPT Code	Description
M0201	COVID-19 vaccine home admin. <i>Effective 6/08/2021</i>
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring (<i>Effective 12/08/2021</i>)
M0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency (<i>Effective 12/08/2021</i>)
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring (<i>Effective 2/11/2022</i>)
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency (<i>Effective 2/11/2022</i>)
M0240	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses (<i>Effective 7/30/2021</i>)
M0243	intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring
M0244	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency. (<i>Effective 05/06/2021</i>)
M0245	intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
M0246	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency. <i>Effective 5/06/2021</i>
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring. <i>Effective 5/26/2021</i>

Reimbursement Policy:

COVID-19 Vaccine and Monoclonal Antibody Infusions Policy

CPT Code	Description
M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency. <i>Effective 5/06/2021</i>
M0249	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose. <i>Effective 6/24/2021</i>
M0250	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose. <i>Effective 6/24/2021</i>
Q0239	Injection, bamlanivimab-xxxx, 700 mg
Q0243	Injection, casirivimab and imdevimab, 2400 mg
Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg (<i>Effective 12/08/2021</i>)
Q0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg (<i>Effective 2/24/2022</i>)
Q0222	Injection, bebtelovimab, 175 mg (<i>Effective 2/11/2022</i>)
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg
Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg. <i>Effective 6/24/2021</i>

Reimbursement Policy:

COVID-19 Vaccine and Monoclonal Antibody Infusions Policy

CPT Code	Description
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose (<i>Pfizer Administration – first dose</i>)
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose (<i>Pfizer Administration – second dose</i>)
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose (<i>Pfizer Administration-Third Dose Effective 8/12/2021</i>)
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose (<i>Moderna Administration - first dose</i>)
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose (<i>Moderna Administration – second dose</i>)
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; third dose (<i>Moderna Administration – Third Dose Effective 8/12/2021</i>)
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, single dose (<i>Janssen Administration – first dose</i>)
0041A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose (<i>Novavax Administration-first dose Effective 7/13/2022</i>)
0042A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose (<i>Novavax Administration-second dose Effective 7/13/2022</i>)

Reimbursement Policy:

COVID-19 Vaccine and Monoclonal Antibody Infusions Policy

CPT Code	Description
0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose (<i>Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - First dose</i>) Effective 1/03/2022
0052A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose (<i>Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - Second dose</i>) Effective 1/03/2022
0053A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose (<i>Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - Third dose</i>) Effective 1/03/2022
0054A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose (<i>Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration – Booster</i>) Effective 1/03/2022
0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose) (<i>Moderna Covid-19 Vaccine (Low Dose) Administration – Booster</i>) Effective 10/20/2021
0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose. (<i>Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - First dose</i>) Effective 10/29/2021
0072A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose (<i>Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - Second dose</i>) Effective 10/29/2021
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose (<i>Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - Third dose</i>) Effective 1/03/2022

Reimbursement Policy:

COVID-19 Vaccine and Monoclonal Antibody Infusions Policy

CPT Code	Description
0074A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose (<i>Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) Administration – Booster Effective 5/17/2022</i>)
0081A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose (<i>Pfizer-BioNTech COVID-19 vaccine for children in the age range of 6 months to 5 years Effective 6/17/2022</i>)
0082A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose (<i>Pfizer-BioNTech COVID-19 vaccine for children in the age range of 6 months to 5 years Effective 6/17/2022</i>)
0083A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose (<i>Pfizer ages 6 months through 4 years – 3rd dose Effective 6/17/2022</i>)
0091A	Moderna Covid-19 Pediatric Vaccine (Aged 6 years through 11 years) (Blue Cap with purple border) Administration - First dose <i>Effective 6/17/2022</i>
0092A	Moderna Covid-19 Pediatric Vaccine (Aged 6 years through 11 years) (Blue Cap with purple border) Administration - Second dose <i>Effective 6/17/2022</i>
0093A	Moderna Covid-19 Pediatric Vaccine (Aged 6 years through 11 years) (Blue Cap with purple border) Administration - Third dose <i>Effective 6/17/2022</i>
0094A	Moderna COVID-19 Vaccine (Blue Cap) 50MCG/0.5ML Administration – Booster <i>Effective 3/29/2022</i>
0111A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose (<i>Moderna ages 6 months through 5 years – first dose Effective 6/17/2022</i>)
0112A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose (<i>Moderna ages 6 months through 5 years – second dose Effective 6/17/2022</i>)
0113A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose (<i>Moderna ages 6 months through 5 years – third dose Effective 6/17/2022</i>)

Reimbursement Policy:

COVID-19 Vaccine and Monoclonal Antibody Infusions Policy

CPT Code	Description
91300	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use (<i>Pfizer-BioNTech Covid-19 Vaccine (Aged 12 years and older) (Purple Cap)</i>)
91301	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use (<i>Moderna Covid-19 Vaccine (Aged 12 years and older) (Red Cap)</i>)
91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use (<i>Janssen Covid-19 Vaccine (Aged 18 years and older)</i>)
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use (<i>Novavax Ages 18 and older Effective 7/13/2022</i>)
91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use (<i>Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Ages 12 years and older Effective 1/03/2022</i>)
91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use (<i>Moderna Covid-19 Vaccine (Low Dose) (Red Cap) Ages 18 years and older. Effective 10/20/2021</i>)
91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (<i>Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) Ages 5 years through 11 years Effective 10/29/2021</i>)
91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (<i>Pfizer-BioNTech COVID-19 vaccine for children in the age range of 6 months to 4 years Effective 6/17/2022</i>)
91309	Moderna Covid-19 Vaccine (Aged 6 years through 11 years or aged 18 years and older) (Blue Cap with purple border) 50MCG/0.5ML <i>Effective 3/29/2022</i>
91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use (Blue Cap with magenta border) (<i>Moderna ages 6 months through 5 years Effective 6/17/2022</i>)
Revenue Code – 771	Both the monoclonal antibody and vaccines for COVID-19 should be coded under revenue code 0771 per CMS.

Reimbursement Policy:

COVID-19 Vaccine and Monoclonal Antibody Infusions Policy

Revision History

Company(ies)	DATE	REVISION
EmblemHealth ConnectiCare	11/2020	<ul style="list-style-type: none"> New Policy
EmblemHealth ConnectiCare	02/2021	<ul style="list-style-type: none"> Clarified that Contracted Rates will prevail before Medicare rates Added correct Revenue code for billing
EmblemHealth ConnectiCare	03/2021	<ul style="list-style-type: none"> Added new codes 0031A, 91303, Q0245, M0245
EmblemHealth ConnectiCare	05/2021	<ul style="list-style-type: none"> Added new code M0244 (effective 5/6/2021); removed M0239 (effective 4/16/2021)
EmblemHealth ConnectiCare	06/2021	<ul style="list-style-type: none"> Added new codes M0246 & M0248 (effective 5/6/2021), M0247 (effective 5/26/2021) and M0201 (effective 6/08/2021)
EmblemHealth ConnectiCare	08/2021	<ul style="list-style-type: none"> Added new codes Q0249, M0249 & M0250 effective 6/24/2021
EmblemHealth ConnectiCare	8/17/2021	<ul style="list-style-type: none"> Added new codes 0003A & 0013A effective 8/12/2021
EmblemHealth ConnectiCare	2/03/2022	<ul style="list-style-type: none"> Added new codes 91308, 0081A & 0082A Effective 2/01/2022 Added new codes 91305, 0051A, 0052A, 0053A, 0054A and 0073A Effective 1/03/2022 Added new codes 91306 & 0064A Effective 10/20/2021 Added new codes 91307, 0071A, 0072A Effective 10/29/2021 Reformatted and reorganized policy, transferred content to new template with new Reimbursement Policy Number

Reimbursement Policy:
COVID-19 Vaccine and Monoclonal
Antibody Infusions Policy

Company(ies)	DATE	REVISION
EmblemHealth ConnectiCare	4/11/2022	<ul style="list-style-type: none"> Added new code M0240 Effective 7/30/2021 Added new codes Q0220, M0220 & M0221 Effective 12/08/2021 Added new codes Q0222, M0222, M0223 Effective 2/11/2022 Added new code Q0221 Effective 2/24/2022
EmblemHealth ConnectiCare	5/05/2022	<ul style="list-style-type: none"> Added new codes effective 3/29/2022: 91309 & 0094A
EmblemHealth ConnectiCare	6/09/2022	<ul style="list-style-type: none"> Added new code 0074A effective 5/17/2022
EmblemHealth ConnectiCare	7/22/2022	<ul style="list-style-type: none"> Added new codes effective 6/17/2022: 0083A, 0091A, 0092A, 0093A, 0111A, 0112A, 0113A, 91308 and 91311 Added new codes effective 7/13/2022: 0041A, 0042A and 91304